Scholtz & Company Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$3.84M |
| 2 |
Tetra Tech
TTEK
|
+$3.65M |
| 3 |
Southern Copper
SCCO
|
+$3.38M |
| 4 |
Intuitive Surgical
ISRG
|
+$2.68M |
| 5 |
Madison Square Garden
MSGE
|
+$2.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$6.37M |
| 2 |
Waste Management
WM
|
+$4.23M |
| 3 |
Franco-Nevada
FNV
|
+$2.93M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$2.16M |
| 5 |
UnitedHealth
UNH
|
+$2.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.78% |
| 2 | Technology | 19.68% |
| 3 | Consumer Discretionary | 16.62% |
| 4 | Communication Services | 14.99% |
| 5 | Industrials | 12.09% |
No holdings matched the selected filter criteria.
Similar funds
Scholtz & Company's Q1 2026 Portfolio in Review
As of Q1 2026, Scholtz & Company held 58 positions worth $195M, down 15% from $230M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Scholtz & Company withdrew a net $13.7M in Q1 2026, closing 9 positions and reducing 24 holdings. Its most notable exit was Intuit, an estimated $6.37M position sold in full.
By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Scholtz & Company opened a new position in Boston Scientific worth $3.01M.
- Scholtz & Company's largest Q1 2026 buy was Boston Scientific: 47,957 shares worth $3.01M.
- Scholtz & Company added most to Valvoline in Q1 2026, an estimated $1.59M increase.
- Scholtz & Company's biggest Q1 2026 reduction was Alphabet (Google) Class A, cutting an estimated $2.16M.
- Scholtz & Company fully exited Intuit in Q1 2026, selling an estimated $6.37M.
- Scholtz & Company's ten largest holdings make up 48% of its $195M portfolio in Q1 2026.
- Scholtz & Company opened 6 new positions and closed 9 in Q1 2026.
- Scholtz & Company's portfolio value fell 15% quarter-over-quarter to $195M.
Based on Scholtz & Company's 13F filing for Q1 2026, filed 15 May 2026.